{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:40:30Z","timestamp":1792017630532,"version":"4.4.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Drug repositioning, that is, the use of a drug in an indication other than the one for which it was initially marketed, is a growing trend. Its origins lie mainly in the attrition experienced in recent years in the field of new drug discovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Key findings<\/jats:title>\n                    <jats:p>Despite some regulatory and economic challenges, drug repositioning offers many advantages, and a number of recent successes have confirmed both its public health benefits and its commercial value. The first examples of successful drug repositioning mainly came about through serendipity like acetylsalicylic acid, thalidomide, sildenafil or dimethylfumarate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The history of great-repositioned drugs has given some solutions to various pathologies. Serendipity is not yet useful to find repositioning drugs. Drug repositioning is of growing interest. Nowadays, a more rational approach to the identification of drug candidates for repositioning is possible, especially using data mining.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jphp.13273","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T07:25:20Z","timestamp":1587108320000},"page":"1145-1151","source":"Crossref","is-referenced-by-count":440,"title":["Drug repositioning: a brief overview"],"prefix":"10.1093","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0553-9705","authenticated-orcid":false,"given":"Jean-Pierre","family":"Jourdan","sequence":"first","affiliation":[{"name":"UNICAEN, Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie (CERMN), Normandie Univ. , Caen,","place":["France"]},{"name":"Pharmacy Department, CHRU de Caen , Caen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan","family":"Bureau","sequence":"additional","affiliation":[{"name":"UNICAEN, Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie (CERMN), Normandie Univ. , Caen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rochais","sequence":"additional","affiliation":[{"name":"UNICAEN, Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie (CERMN), Normandie Univ. , Caen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4845-615X","authenticated-orcid":false,"given":"Patrick","family":"Dallemagne","sequence":"additional","affiliation":[{"name":"UNICAEN, Centre d\u2019Etudes et de Recherche sur le M\u00e9dicament de Normandie (CERMN), Normandie Univ. , Caen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,1]]},"reference":[{"key":"2024103012352268400_jphp13273-cit-0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012352268400_jphp13273-cit-0002","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discov"},{"key":"2024103012352268400_jphp13273-cit-0003","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001","article-title":"Drug repositioning and repurposing: terminology and definitions in literature","volume":"20","author":"Langedijk","year":"2015","journal-title":"Drug Discov Today"},{"key":"2024103012352268400_jphp13273-cit-0004","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S1359-6446(05)03686-X","article-title":"Selective optimization of side activities: the SOSA approach","volume":"11","author":"Wermuth","year":"2006","journal-title":"Drug Discov Today"},{"key":"2024103012352268400_jphp13273-cit-0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fphar.2017.00298","article-title":"On the integration of in silico drug design methods for drug repurposing","volume":"8","author":"March-Vila","year":"2017","journal-title":"Front Pharmacol"},{"key":"2024103012352268400_jphp13273-cit-0006","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1021\/ci500670q","article-title":"Systematic drug repositioning for a wide range of diseases with integrative analyses of phenotypic and molecular data","volume":"55","author":"Iwata","year":"2015","journal-title":"J Chem Inf Model"},{"key":"2024103012352268400_jphp13273-cit-0007","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.drudis.2017.03.009","article-title":"Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases","volume":"22","author":"Dovrolis","year":"2017","journal-title":"Drug Discov Today"},{"key":"2024103012352268400_jphp13273-cit-0008","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"2024103012352268400_jphp13273-cit-0009","first-page":"50","article-title":"Therapeutic drug repurposing: repositioning and rescue","author":"Naylor","year":"2014","journal-title":"Drug Discov World"},{"key":"2024103012352268400_jphp13273-cit-0010","volume-title":"Drug Repurposing|October 1, 2012 Issue \u2013 Vol. 90 Issue 40|Chemical & Engineering News","author":"Thayer"},{"key":"2024103012352268400_jphp13273-cit-0011","first-page":"3","article-title":"Scientific commercial value of drug repurposing","author":"Cavalla","year":"2017"},{"key":"2024103012352268400_jphp13273-cit-0012","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nbt.3183","article-title":"Opportunities for drug repositioning from phenome-wide association studies","volume":"33","author":"Rastegar-Mojarad","year":"2015","journal-title":"Nat Biotechnol"},{"key":"2024103012352268400_jphp13273-cit-0013","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/bib\/bbr006","article-title":"Database identifies FDA-approved drugs with potential to be repurposed for treatment of orphan diseases","volume":"12","author":"Xu","year":"2011","journal-title":"Brief Bioinform"},{"key":"2024103012352268400_jphp13273-cit-0014","article-title":"Fabuleux hasards: histoire de la d\u00e9couverte de m\u00e9dicaments","author":"Monneret","year":"2009"},{"key":"2024103012352268400_jphp13273-cit-0015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/newbio231232a0","article-title":"Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs","volume":"231","author":"Vane","year":"1971","journal-title":"Nat New Biol"},{"key":"2024103012352268400_jphp13273-cit-0016","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(10)62110-1","article-title":"Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials","volume":"377","author":"Rothwell","year":"2011","journal-title":"Lancet"},{"key":"2024103012352268400_jphp13273-cit-0017","doi-asserted-by":"crossref","first-page":"11301","DOI":"10.1073\/pnas.95.19.11301","article-title":"Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection","volume":"95","author":"R\u00fcschoff","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2024103012352268400_jphp13273-cit-0018","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM199911183412110","article-title":"Thalidomide \u2013 a revival story","volume":"341","author":"Raje","year":"1999","journal-title":"N Engl J Med"},{"key":"2024103012352268400_jphp13273-cit-0019","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","article-title":"Alzheimer\u2019s disease drug development pipeline: 2017","volume":"3","author":"Cummings","year":"2017","journal-title":"Alzheimer\u2019s Dement Transl Res Clin Interv"},{"key":"2024103012352268400_jphp13273-cit-0020","article-title":"Chloroquine and hydroxychloroquine as available weapons to fight COVID-19","author":"Raoult","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2024103012352268400_jphp13273-cit-0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168812","article-title":"Drug repositioning for Alzheimer\u2019s disease based on systematic \u201comics\u201d data mining","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS ONE"},{"key":"2024103012352268400_jphp13273-cit-0022","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2017.29","article-title":"A standard database for drug repositioning","volume":"4","author":"Brown","year":"2017","journal-title":"Sci Data"},{"key":"2024103012352268400_jphp13273-cit-0023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrd3681","article-title":"Diagnosing the decline in pharmaceutical R&D efficiency","volume":"11","author":"Scannell","year":"2012","journal-title":"Nat Rev Drug Discov"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjphp.13273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jphp.13273","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jphp.13273","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/9\/1145\/60226489\/jphp13273.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/72\/9\/1145\/60226489\/jphp13273.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:01:46Z","timestamp":1730296906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/72\/9\/1145\/6132671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,1]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9,1]]},"published-print":{"date-parts":[[2020,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jphp.13273","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9]]},"published":{"date-parts":[[2020,9,1]]}}}